Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

EYPT

EyePoint Inc

Mar 09 • 04:00PM ET

15.67

-0.08 -0.51 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN ALNY VRTX NBIX BMRN IONS SAGE RARE AGIO BLUE

| Held by: VTI IWM VXF IWN SCHA XPH VTWO PINK IHE IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.16	Insider Own	12.26%	Shs Outstand	82.83M	Perf Week	-14.56%
Market Cap	1.31B	Forward P/E	-	EPS next Y	-3.57	Insider Trans	-1.16%	Shs Float	73.21M	Perf Month	23.10%
Enterprise Value	1.02B	PEG	-	EPS next Q	-0.81	Inst Own	90.59%	Short Float	13.02%	Perf Quarter	-6.28%
Income	-231.96M	P/S	41.68	EPS this Y	-1.58%	Inst Trans	16.85%	Short Ratio	6.81	Perf Half Y	11.85%
Sales	31.37M	P/B	4.24	EPS next Y	-10.81%	ROA	-59.29%	Short Interest	9.53M	Perf YTD	-14.23%
Book/sh	3.70	P/C	4.27	EPS next 5Y	28.18%	ROE	-72.19%	52W High	19.11 -18.00%	Perf Year	119.78%
Cash/sh	3.67	P/FCF	-	EPS past 3/5Y	-4.94% 2.18%	ROIC	-70.96%	52W Low	3.91 300.77%	Perf 3Y	482.53%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.83% -1.85%	Gross Margin	90.59%	Volatility	8.25% 8.63%	Perf 5Y	54.23%
Dividend TTM	-	EV/Sales	32.65	EPS Y/Y TTM	-36.74%	Oper. Margin	-775.96%	ATR (14)	1.23	Perf 10Y	-45.59%
Dividend Ex-Date	-	Quick Ratio	8.83	Sales Y/Y TTM	-27.50%	Profit Margin	-739.39%	RSI (14)	48.18	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	8.88	EPS Q/Q	-26.98%	SMA20	-0.52%	Beta	1.82	Target Price	37.42
Payout	-	Debt/Eq	0.07	Sales Q/Q	-94.65%	SMA50	-0.66%	Rel Volume	1.02	Prev Close	15.75
Employees	214	LT Debt/Eq	0.07	Earnings	Mar 04 BMO	SMA200	22.21%	Avg Volume	1.40M	Price	15.67
IPO	Jan 27, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.35% -37.66%	Trades		Volume	1,428,072	Change	-0.51%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Initiated	RBC Capital Mkts	Outperform	$28
Jan-07-25	Initiated	Citigroup	Buy	$33
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-22-24	Initiated	JP Morgan	Overweight	$35
Nov-02-23	Initiated	Mizuho	Buy	$20
Apr-21-23	Initiated	Robert W. Baird	Outperform	$33
Jul-07-22	Initiated	Chardan Capital Markets	Buy	$21
Mar-01-21	Initiated	Cowen	Outperform	$25
Jan-28-21	Initiated	Cantor Fitzgerald	Overweight	$22
Apr-06-20	Downgrade	B. Riley FBR	Buy → Neutral	$4 → $1
Nov-04-19	Resumed	Laidlaw	Buy	$5
Sep-12-19	Initiated	Guggenheim	Buy

Show Previous Ratings

Mar-04-26 04:03PM	EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... (GuruFocus.com) -12.44%
12:36PM	EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
10:36AM	Eyepoint Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
08:20AM	EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:23AM	EyePoint: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-02-26 07:00AM	EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU for the Treatment of Diabetic Macular Edema (GlobeNewswire)
Feb-26-26 12:15PM	Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates (Zacks)
Feb-25-26 07:00AM	EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 (GlobeNewswire)
Feb-24-26 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-18-26 07:58AM	EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains? (Zacks)
07:00AM	EyePoint Appoints Michael Campbell as Chief Commercial Officer (GlobeNewswire)
Feb-17-26 08:30AM	Ocular Therapeutix stock news: Why positive data led to a 25% drop (Investing.com) +15.22%
07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-26 09:40AM	Wall Street Thinks These 4 Biotech Stocks Will DoubleAt LeastThis Year (24/7 Wall St.)
05:12PM	Loading…
Feb-13-26 05:12PM	EyePoint Pharmaceuticals Teases Mid-2026 DURAVYU Wet AMD Data, Starts Phase III DME Program (MarketBeat) +15.22%
Feb-05-26 07:00AM	EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-26 07:00AM	EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 (GlobeNewswire)
Dec-22-25 12:00PM	EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know (Zacks) +8.15%
08:10AM	3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 (Zacks)
Dec-20-25 12:00PM	The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside (Barchart)
Dec-17-25 07:00AM	EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-19-25 07:00AM	EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration (GlobeNewswire)
Nov-17-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +13.43%
Nov-07-25 04:00AM	EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-05-25 08:15AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -11.10%
07:22AM	EyePoint Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
08:06AM	Loading…
Nov-04-25 08:06AM	EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-03-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-29-25 07:00AM	EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-14-25 10:43PM	EyePoint Announces Pricing of Public Offering (GlobeNewswire) -10.87%
04:35PM	EyePoint Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema (GlobeNewswire)
Sep-25-25 09:29AM	Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks) -6.32%
Sep-23-25 01:13PM	Biotech Stocks Rally. 3 Favorite Plays From the Charts. (Barrons.com)
Sep-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 04:01PM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-25 08:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire)
07:26AM	EyePoint Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Aug-05-25 10:08AM	EyePoint Pharmaceuticals Inc (EYPT) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +8.25%
Jul-30-25 06:00PM	Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:00AM	EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
05:57AM	Enrolment concludes in EyePoints Phase III programme of Duravyu for wet AMD (Clinical Trials Arena)
Jul-29-25 07:00AM	EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration (GlobeNewswire)
Jul-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:54AM	Breakout Momentum Plays You May Not Know About (MarketBeat) +8.36%
May-28-25 04:01PM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire) +18.12%
May-27-25 07:00AM	EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
May-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.17%
May-13-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
May-07-25 02:49PM	Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum (Seeking Alpha)
02:49PM	EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:25AM	EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:22AM	EyePoint Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Apr-30-25 07:00AM	EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-25 07:00AM	EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference (GlobeNewswire)
Mar-17-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-06-25 02:14AM	Q4 2024 EyePoint Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... (GuruFocus.com)
Mar-05-25 09:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks) +8.22%
08:25AM	EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:34AM	EyePoint Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-04-25 07:17AM	Earnings To Watch: EyePoint Pharmaceuticals Inc (EYPT) Reports Q4 2024 Result (GuruFocus.com) +6.29%
07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-26-25 07:00AM	EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025 (GlobeNewswire)
Feb-25-25 07:00AM	EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-17-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-25 07:00AM	EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema Meeting Primary and Secondary Endpoints (GlobeNewswire)
Jan-30-25 07:00AM	EyePoint to Present at Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.46%
Jan-13-25 07:00AM	EyePoint Provides Company Update and Anticipated Development Milestones for 2025 (GlobeNewswire) -7.07%
Jan-08-25 07:00AM	EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors (GlobeNewswire)
Dec-17-24 07:25AM	EyePoint reports inducement grants under NASDAQ listing rule (TipRanks) +5.39%
07:00AM	EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-05-24 07:06AM	EyePoint doses first patient in second Phase 3 LUCIA clinical trial (TipRanks)
Dec-04-24 07:00AM	EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Nov-18-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -6.43%
Nov-13-24 09:55AM	Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High? (Zacks)
Nov-12-24 06:45AM	EyePoint price target lowered to $33 from $38 at Baird (TipRanks) -7.42%
Nov-07-24 08:35AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:37AM	EyePoint Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Nov-04-24 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-31-24 04:00PM	EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares (GlobeNewswire)
Oct-29-24 09:47PM	EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering (GlobeNewswire)
04:49AM	EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-28-24 05:14PM	EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire) +27.58%

EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ribeiro Ramiro	Chief Medical Officer	Mar 04 '26	Option Exercise	8.26	2,438	20,138	2,438	Mar 05 04:02 PM
Ribeiro Ramiro	Chief Medical Officer	Mar 04 '26	Sale	17.87	2,438	43,572	0	Mar 05 04:02 PM
Ribeiro Ramiro	Chief Medical Officer	Feb 17 '26	Option Exercise	8.26	2,437	20,130	2,437	Feb 18 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Feb 17 '26	Sale	15.00	2,437	36,555	0	Feb 18 04:07 PM
Lurker Nancy	Director	Jan 06 '26	Option Exercise	0.00	75,133	0	294,346	Jan 07 04:13 PM
Duker Jay S.	President and CEO	Jan 06 '26	Option Exercise	0.00	20,793	0	87,806	Jan 07 04:12 PM
Elston George	Chief Financial Officer	Jan 06 '26	Option Exercise	0.00	15,285	0	96,339	Jan 07 04:12 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 05 '26	Option Exercise	8.26	29,250	241,605	42,544	Jan 07 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 05 '26	Sale	17.10	42,544	727,319	0	Jan 07 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 03 '26	Option Exercise	0.00	19,667	0	19,667	Jan 06 04:47 PM
Duker Jay S.	President and CEO	Jan 05 '26	Option Exercise	0.00	30,000	0	81,518	Jan 06 04:10 PM
Duker Jay S.	President and CEO	Jan 03 '26	Option Exercise	0.00	65,000	0	74,965	Jan 06 04:10 PM
Elston George	Chief Financial Officer	Jan 05 '26	Option Exercise	0.00	15,000	0	85,457	Jan 06 04:10 PM
Elston George	Chief Financial Officer	Jan 03 '26	Option Exercise	0.00	19,667	0	76,781	Jan 06 04:10 PM
Lurker Nancy	Director	Jan 05 '26	Option Exercise	0.00	12,666	0	219,213	Jan 06 04:07 PM
Ramiro Ribeiro	Officer	Jan 05 '26	Proposed Sale	17.48	53,792	940,284		Jan 05 04:42 PM
Cormorant Asset Management, LP	Former 10% Owner	Dec 04 '25	Sale	15.70	60,000	942,240	8,265,000	Dec 08 04:03 PM
Lurker Nancy	Director	Dec 04 '25	Sale	15.11	9,300	140,477	206,547	Dec 05 04:06 PM
Lurker Nancy	Officer	Dec 04 '25	Proposed Sale	15.11	9,300	140,477		Dec 04 10:24 AM
Lurker Nancy	Director	Nov 28 '25	Sale	14.95	500	7,475	215,847	Dec 01 04:09 PM
Lurker Nancy	Director	Nov 26 '25	Sale	14.95	200	2,990	216,347	Dec 01 04:09 PM
Lurker Nancy	Officer	Nov 28 '25	Proposed Sale	14.95	500	7,475		Nov 28 01:23 PM
Lurker Nancy	Officer	Nov 26 '25	Proposed Sale	14.95	200	2,990		Nov 26 04:09 PM
Ribeiro Ramiro	Chief Medical Officer	Nov 11 '25	Sale	11.61	2,722	31,602	0	Nov 12 04:03 PM
Ramiro Ribeiro	Officer	Nov 11 '25	Proposed Sale	11.35	2,722	30,895		Nov 12 06:55 AM
Zaderej Karen L.	Director	Jul 11 '25	Option Exercise	0.00	2,000	0	38,500	Jul 11 04:07 PM
Lurker Nancy	Director	Jul 10 '25	Option Exercise	0.00	11,111	0	216,547	Jul 11 04:06 PM
Duker Jay S.	President and CEO	Jul 10 '25	Option Exercise	0.00	16,667	0	17,653	Jul 11 04:06 PM
Elston George	Chief Financial Officer	May 25 '25	Option Exercise	0.00	7,500	0	83,050	May 27 04:08 PM
Zaderej Karen L.	Director	May 19 '25	Buy	5.99	5,000	29,950	36,500	May 19 04:06 PM
Zaderej Karen L.	Director	May 16 '25	Buy	5.81	5,000	29,050	31,500	May 19 04:06 PM
Zaderej Karen L.	Director	May 15 '25	Buy	5.47	5,000	27,350	26,500	May 15 04:06 PM
Zaderej Karen L.	Director	May 14 '25	Buy	5.42	5,000	27,100	21,500	May 15 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EYPT

EyePoint Inc

Upgrade your FINVIZ experience